Stock Market Impact: Zealand Pharma A/S shares sank more than 24% on Monday, trading at DKK 247.30 after the release of Phase III trial data for its obesity drug SURVODUTIDE.
Listed Companies and Sectors: The information concerns Zealand Pharma A/S (pharmaceutical/biotech) and its licensee Boehringer Ingelheim, impacting the obesity‑drug and GLP‑1 therapeutic segment.
Investment Flows: No explicit FDI/FPI activity is mentioned; however, analyst price targets were revised (Barclays target DKK 425, Wolfe Research target DKK 750), reflecting altered valuation expectations.
Interest Rates, Inflation, and Liquidity: The article contains no references to monetary policy, interest rates, or liquidity conditions.
Fiscal or Monetary Policy: No fiscal or monetary policy measures are discussed.
Detailed Trial Findings
SYNCHRONIZE‑1 (Obesity/Overweight, no Type 2 Diabetes): Conducted over 76 weeks in 725 adults. Weight loss reached up to 16.6% (efficacy estimand) versus 3.2% for placebo. Discontinuation due to adverse events occurred in 23.7% of patients on the 3.6 mg dose and 24.8% on the 6 mg dose, compared with 5.4% on placebo. Gastro‑intestinal (GI) events were reported in 17.8% (3.6 mg) and 20.2% (6 mg) versus 2.9% on placebo; vomiting was observed in up to 44.6% of patients on the highest dose.
MRI Body‑Composition Sub‑Study (75 patients): SURVODUTIDE 6 mg produced a 34% relative reduction in visceral fat versus 11.8% for placebo, a 63.1% reduction in liver fat versus 24.5% for placebo, and lean‑mass gain accounted for no more than 10.8% of total tissue‑mass change. The sub‑study included only 25 patients per arm, making results hypothesis‑generating.
SYNCHRONIZE‑MASLD (Obesity with Metabolic Dysfunction‑Associated Steatotic Liver Disease): 48‑week trial in 218 adults. 84.2% of SURVODUTIDE‑treated patients achieved at least a 30% relative liver‑fat reduction versus 24.3% on placebo. Body‑weight loss was 12.2% versus 1% for placebo (efficacy estimand). Liver‑fat normalization (<5%) occurred in 61% of treated patients versus 5.7% on placebo. Adverse‑event‑related discontinuation was 23.3% versus 10% on placebo; nausea reported in 56.2% and vomiting in 42.5% of treated patients.
Analyst Commentary
Barclays: Maintains an “overweight” rating with a price target of DKK 425 (≈72% upside from the post‑drop level of DKK 247.30). Describes the safety and tolerability profile as “disappointing,” though acknowledges strong signals on body composition and liver health. Anticipates similar safety issues in upcoming Phase 3 readouts (SYNCHRONIZE‑2 and SYNCHRONIZE‑CVOT, due H2 2026).
Wolfe Research: Holds an “outperform” rating with a price target of DKK 750 (≈129.8% upside from the pre‑drop close). Highlights the high discontinuation rate as a risk, notes that 16.5% of placebo‑arm patients used a prohibited GLP‑1 receptor agonist, which may have narrowed the apparent treatment gap.
Commercial Outlook
SURVODUTIDE is licensed to Boehringer Ingelheim, which is solely responsible for global development and commercialization.
Zealand Pharma is eligible for high single‑ to low double‑digit royalty percentages on worldwide SURVODUTIDE sales and up to €315 million in potential outstanding milestone payments.
The drug could launch as late as 2027, becoming the third incretin‑based therapy to reach US and EU markets, but analysts do not expect it to meaningfully change the overall GLP‑1 market.
